Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways
Leo I. Gordon; Michael A. Burke; Amareshwar T. K. Singh; Sheila Prachand; Elliot D. Lieberman; Lin Sun; Tejaswitha Jairaj Naik; Sathyamangla V. Naga Prasad; Hossein Ardehali (Profiled Authors: Hossein Ardehali; Leo I Gordon; Amareshwar Singh)
Journal of Biological Chemistry. 2009;284(4):2080-2087.Abstract
Overexpression of the receptor tyrosine kinase erbB2 (Her2 in humans) is correlated with a poor prognosis in breast and ovarian cancers. Treatment with trastuzumab (a monoclonal antibody against erbB2) improves survival; however, it also causes cardiomyopathy. We hypothesized that blockade of the erbB2 receptor induces cardiomyocyte death through a mitochondrial pathway that is dependent on the production of reactive oxygen species (ROS). We first showed that levels of erbB2 receptor are significantly decreased in an animal model of ischemic heart disease and in human ischemic cardiomyopathy. We treated neonatal rat cardiomyocytes with an inhibitory erbB2 antibody to study the mechanism behind the deleterious effects of erbB2 blockade. These cells displayed a dose-dependent increase in ROS production and cell death compared with control IgG-treated cells; these processes were reversed by the antioxidant, N-acetylcysteine. The effects of erbB2 antibody on both cell death and ROS production were also reversed by cyclosporineA and diazoxide, chemicals that regulate the pro- and anti-apoptotic channels in the mitochondria, respectively. Furthermore, mouse embryonic fibroblasts lacking Bax and Bak (proteins that mediate cell death through a mitochondrial pathway) were resistant to the deleterious effects of erbB2 antibody. These effects of erbB2 blockade appear to occur through a pathway involving AKT and PKC-α. Our results suggest that erbB2 plays a role in cardiomyocyte survival, and that the deleterious effects of trastuzumab on the heart occur through a mitochondrial pathway and is mediated by ROS production. Manipulation of redox signaling may be beneficial in cancer patients receiving trastuzumab. © 2009 by The American Society for Biochemistry and Molecular Biology, Inc.
PMID: 19017630 PMCID: PMC2629107
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Vivian M. Dezengotita; William M. Miller; John G. Aunins; Weichang ZhouBiotechnology and Bioengineering. 2000;69(5):566-576.
Michael E. Werner; Feng Chen; Jose V. Moyano; Fruma Yehiely; Jonathan C. R. Jones; Vincent L. CrynsJournal of Biological Chemistry. 2007;282(8):5560-5569.
C. Daniels; G. AmeerTransactions - 7th World Biomaterials Congress. 2004:560.
Appears in this Document